News | Cath Lab | March 04, 2016

GlobalData: Stenting Viable Alternative to Surgery in Carotid Artery Stenosis

Opposing procedures show similar rates of adverse events and restenosis in CREST trial

CREST trial results, New England Journal of Medicine, stenting, endarterectomy, carotid artery stenosis

March 4, 2016 — Recent results from the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) are evidence that stenting will continue to remain competitive with surgical treatment, said an analyst with research and consulting firm GlobalData. CREST data has shown patients with severe carotid artery stenosis suffered similar rates of adverse events in both stenting and endarterectomy procedures.

The 10-year findings of the trial, published by the New England Journal of Medicine, showed adverse event rates of 11.8 percent in stenting and 9.9 percent in endarterectomy groups, with no significant difference in restenosis rates. In this way, both procedures exhibit similar long-term, post-procedural safety and efficacy profiles.

Premdharan Meyyan, GlobalData's analyst covering medical devices, states that in order for stenting to experience increased uptake, developers should prioritize improving solutions for embolic protection to minimize periprocedural stroke risk.

Meyyan said: “Carotid stenting systems with flow reversal and integrated embolic protection have potential to address the challenges with the current generation of products. GlobalData expects there will be an increased demand for these systems in coming years.

“Indeed, major peripheral vascular players that have developed and launched proximal embolic protection systems that incorporate flow reversal or arrest, with high rates of technical success, include Medtronic with its MoMa Ultra, and W.L Gore with its Gore Flow Reversal System.”

The analyst added that mesh-covered stents are also emerging as a potential solution to the periprocedural stroke rate. InspireMD has developed the CE-marked CGuard nitinol stent, which utilizes a polyethylene terephthalate mesh to provide continuous embolic protection, showing 100 percent procedural success and no major adverse events at the 30-day mark. 

Meyyan concluded: “These new technologies are promising, and show that opportunities continue to be available for companies to devise carotid artery stenting systems.

“Despite stenting’s stable reputation following the CREST trial results, the outcome from the CREST-2 trial, which compares clinical outcomes of surgery, stenting and medical therapy, will be pivotal in determining the future direction of carotid artery disease management.”

For more information: www.globaldata.com

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now